Morgan Stanley Increases HSP 1Q11 Estimates

Morgan Stanley has increased its first quarter estimates for Hospira HSP. According to the report, “We are increasing our 1Q EPS estimate to $0.79 from $0.65 and revenues from $893MM to $939MM more or less in-line with the updated guidance. For the full year, our EPS estimate rises to $4.00 from $3.96 as we shift generic Taxotere revenues and EPS into 1Q with modest upside to our market share assumptions for the full year.” HSP closed at $54.01 yesterday.